Oldest pages

Jump to navigation Jump to search

Showing below up to 50 results in range #5,101 to #5,150.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Du Z (1st author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  2. Wang L (2nd author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  3. Cauchemez S (3rd author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  4. Xu X(4th author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  5. Wang X (5th author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  6. Cowling B (6th author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  7. Meyers LA (7th author of DOI /10.3201/eid2605.200146)‏‎ (21:15, 22 June 2020)
  8. Section 2: Methods (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:06, 23 June 2020)
  9. Section 3: Results (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:06, 23 June 2020)
  10. Section 4: Discussion (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:07, 23 June 2020)
  11. Section 5: Future directions (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:07, 23 June 2020)
  12. Section 6: Conclusions (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:07, 23 June 2020)
  13. References (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:09, 23 June 2020)
  14. Section 1: Introduction (from DOI:10.14218/ERHM.2020.00023)‏‎ (15:41, 23 June 2020)
  15. Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  16. Section 2: SARS-CoV-2 Biology and Clinical Implications (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  17. Section 3: Cardiovascular Comorbidities and COVID-19 Outcomes (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  18. Section 3.1: Cardiac Complications of COVID-19 (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  19. Section 3.1.1: Myocardial Injury and Heart Failure (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  20. Section 3.1.2: Arrhythmia (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  21. Section 4: Conclusion (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  22. Conflict of Interest (from DOI: 10.1007/s11886-020-01293-2)‏‎ (15:50, 23 June 2020)
  23. References (from DOI: 10.1007/s11886-020-01293-2)‏‎ (19:12, 23 June 2020)
  24. Section 1: Introduction (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  25. Section 2: Is SARS-CoV-2 a congenital or perinatally-acquired pathogen for the neonate? (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  26. Section 2.1: Lessons from animal models (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  27. Section 2.2: Congenital and perinatal infections with coronaviruses other than SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  28. Section 2.3: Congenital and perinatal infections with SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  29. Section 3: Conclusions and priorities for future research (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  30. Funding (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  31. Declaration of Competing Interest (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  32. References (from DOI: 10.1016/j.jcv.2020.104372)‏‎ (19:29, 23 June 2020)
  33. Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:29, 23 June 2020)
  34. Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  35. Section 3: The Role of Host Immune Response (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  36. Section 4: Viral Toxicity and Myocardial Injury in COVID-2 (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  37. Section 5: Immune Responses to SARS-CoV-2 Infection and the Heart (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  38. Section 6: Host-Specific Variations in COVID-19 Immune Response (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  39. Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  40. Section 8: Conclusion (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  41. Conflict of Interest (from DOI: 10.1007/s11886-020-01292-3)‏‎ (20:30, 23 June 2020)
  42. References (from DOI: 10.1007/s11886-020-01292-3)‏‎ (21:05, 23 June 2020)
  43. Huang C, et al, Lancet (2020), cited as Ref 1 in DOI:10.1007/s11886-020-01292-3‏‎ (21:11, 23 June 2020)
  44. Wang C, et al, Lancet (2020), cited as Ref 2 in DOI:10.1007/s11886-020-01292-3‏‎ (21:11, 23 June 2020)
  45. Su S, et al, Trends Microbiol (2016), cited as Ref 3 in DOI:10.1007/s11886-020-01292-3‏‎ (21:11, 23 June 2020)
  46. Wang D, et al, JAMA - J Am Med Assoc (2020), cited as Ref 4 in DOI:10.1007/s11886-020-01292-3‏‎ (21:12, 23 June 2020)
  47. Zhou F, et al, Lancet (2020), cited as Ref 5 in DOI:10.1007/s11886-020-01292-3‏‎ (21:12, 23 June 2020)
  48. Xu Z, et al, Lancet (2020), cited as Ref 6 in DOI:10.1007/s11886-020-01292-3‏‎ (21:12, 23 June 2020)
  49. Wu Z, et al, JAMA (2020), cited as Ref 7 in DOI:10.1007/s11886-020-01292-3‏‎ (21:12, 23 June 2020)
  50. Dong E, et al, Lancet Infect Dis (2020), cited as Ref 8 in DOI:10.1007/s11886-020-01292-3‏‎ (21:12, 23 June 2020)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:AncientPages"